KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Other Operating Expenses (2016 - 2025)

Neogenomics' Other Operating Expenses history spans 16 years, with the latest figure at $24.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed 0.1% year-over-year to $24.1 million; the TTM value through Dec 2025 reached $119.8 million, up 34.69%, while the annual FY2025 figure was $119.8 million, 41.47% up from the prior year.
  • Other Operating Expenses reached $24.1 million in Q4 2025 per NEO's latest filing, down from $28.9 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $44.1 million in Q2 2025 to a low of $13.7 million in Q1 2021.
  • Average Other Operating Expenses over 5 years is $20.5 million, with a median of $17.8 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: fell 0.89% in 2022, then soared 89.98% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $15.9 million in 2021, then grew by 7.7% to $17.1 million in 2022, then increased by 5.43% to $18.1 million in 2023, then soared by 33.06% to $24.0 million in 2024, then increased by 0.1% to $24.1 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Other Operating Expenses are $24.1 million (Q4 2025), $28.9 million (Q3 2025), and $44.1 million (Q2 2025).